Fill Out a Referral Now

Blog

Vaping Associated Pulmonary Illness
(VAPI)

As of October 1, 2019 more than 1000 cases of lung injury associated with E-cigarette and vaping products have been reported in the US. There has been 1 confirmed case in Quebec and a suspected case in London Ontario.

What we know:
  • Patients affected reported using a Cannabis or Nicotine-containing product or e-cigarette approximately 1 week prior to symptom onset
  • No specific chemical product or chemical cause have been identified at this time
  • Symptoms include flu-like symptoms with difficulty breathing, cough, nausea, diarrhea, abdominal pain and headache.
  • Symptoms include flu-like symptoms with difficulty breathing, cough, nausea, diarrhea, abdominal pain and headache
  • At this time no confirmed case has been linked to vaping whole plant cannabis
What you should do:
  • If you are concerned about the health risks related to vaping, consider not using vaping products
  • If you use vaping products, or have used vaping products in the past, monitor yourself for symptoms of pulmonary illness (e.g., cough, shortness of breath, chest pain) and promptly seek medical attention if you have concerns about your health
  • Be sure to indicate to your health care professional that you currently vape, or have in the past, and what you were vaping.

If you use vaping products, avoid any products from illegal or unregulated sources. Products obtained from the illegal market are not subject to any controls or oversight with respect to safety or quality.


Cannabis oils and sprays sold legally by Licenced Producers and authorized Cannabis Retailers (ie: Ontario Cannabis Store) should only be consumed by oral ingestion. Do not use products obtained from dispensaries or unauthorized retailers. For information on where cannabis can be obtained safely please contact your health care provider or call 1-866-336-ATMA (2862).

Learn About How Medical
Cannabis Can Be Used
CLICK HERE

Exciting News

Atma Medical Clinic is pleased to announce partnership with McMaster University and the Michael G. DeGroote Centre for Medicinal Cannabis Research.

DATACANN intends to capture real-world data on patients who are prescribed cannabinoids for non-cancer chronic pain. Data collected will inform efforts to standardize cannabis-related medical education, monitor trends in clinical outcomes, and determine how to effectively predict the benefits and harms of cannabis use within a prescribed treatment regimen.

Contact Us Today!

Take your first steps toward better health.

Contact